日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

多模式肿瘤非特异性ctDNA分析用于卵巢癌微小残留病灶检测和风险分层:MITO16a/MaNGO-OV2试验结果

Paracchini, L; Velle, A; Di Gennaro, P; Mannarino, L; Ancona, L; Lorusso, D; Cecere, S C; Colombo, N; Beltrame, L; Fagotti, A; Tasca, G; Piemontese, M; Arenare, L; Califano, D; Galdiero, F; Zadro, R; Chiodini, P; Perrone, F; Biagioli, E; D'Incalci, M; Romualdi, C; Pignata, S; Marchini, S

Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial

奥拉帕尼作为铂类耐药性生殖细胞肿瘤的挽救治疗:IGG-02 II期试验

Schepisi, G; Urbini, M; Casadei, C; Gallà, V; Rossetti, S; Basso, U; Lolli, C; Gurioli, G; Petracci, E; Cecere, S C; Ventriglia, J; Zampiga, V; Miserocchi, A; Cangini, I; De Santis, I; Di Napoli, M; Menna, C; Mambelli, G; Pignata, S; De Giorgi, U

Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).

外周单核细胞髓系衍生抑制细胞与接受卡铂+紫杉醇/avelumab治疗的单中心子宫内膜癌患者的分子亚型的关联(MITO-END3试验)

D'Alterio C, Rea G, Napolitano M, Coppola E, Spina A, Russo D, Azzaro R, Mignogna C, Scognamiglio G, Califano D, Arenare L, Schettino C, Pisano C, Cecere S C, Di Napoli M, Passarelli A, Perrone F, Pignata S, Scala S

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial

MITO16A/MaNGO-OV2 试验中检测卵巢癌同源重组缺陷的替代学术方法

Capoluongo, E D; Pellegrino, B; Arenare, L; Califano, D; Scambia, G; Beltrame, L; Serra, V; Scaglione, G L; Spina, A; Cecere, S C; De Cecio, R; Normanno, N; Colombo, N; Lorusso, D; Russo, D; Nardelli, C; D'Incalci, M; Llop-Guevara, A; Pisano, C; Baldassarre, G; Mezzanzanica, D; Artioli, G; Setaro, M; Tasca, G; Roma, C; Campanini, N; Cinieri, S; Sergi, A; Musolino, A; Perrone, F; Chiodini, P; Marchini, S; Pignata, S

Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices

在聚腺苷二磷酸核糖聚合酶抑制剂时代,复发性卵巢癌:是时候重新评估既定的临床实践了。

Bartoletti, M; Cecere, S C; Musacchio, L; Sorio, R; Puglisi, F; Pignata, S